239 related articles for article (PubMed ID: 31935898)
1. Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation.
Teoh V; Tasoulis MK; Gui G
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935898
[TBL] [Abstract][Full Text] [Related]
2. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic mastectomy for the prevention of breast cancer.
Lostumbo L; Carbine N; Wallace J; Ezzo J
Cochrane Database Syst Rev; 2004 Oct; (4):CD002748. PubMed ID: 15495033
[TBL] [Abstract][Full Text] [Related]
5. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
6. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
7. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
8. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?
Tesson S; Richards I; Porter D; Phillips KA; Rankin N; Costa D; Musiello T; Marven M; Butow P
Breast; 2017 Feb; 31():233-240. PubMed ID: 27969575
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
Hartmann LC; Sellers TA; Schaid DJ; Frank TS; Soderberg CL; Sitta DL; Frost MH; Grant CS; Donohue JH; Woods JE; McDonnell SK; Vockley CW; Deffenbaugh A; Couch FJ; Jenkins RB
J Natl Cancer Inst; 2001 Nov; 93(21):1633-7. PubMed ID: 11698567
[TBL] [Abstract][Full Text] [Related]
10. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy.
Davies KR; Cantor SB; Brewster AM
Int J Womens Health; 2015; 7():181-7. PubMed ID: 25678823
[TBL] [Abstract][Full Text] [Related]
11. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
[TBL] [Abstract][Full Text] [Related]
12. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).
Davies KR; Brewster AM; Bedrosian I; Parker PA; Crosby MA; Peterson SK; Shen Y; Volk RJ; Cantor SB
Breast Cancer Res; 2016 Sep; 18(1):93. PubMed ID: 27650678
[TBL] [Abstract][Full Text] [Related]
14. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
15. Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
Terkelsen T; Rønning H; Skytte AB
Acta Oncol; 2020 Jan; 59(1):60-65. PubMed ID: 31379231
[No Abstract] [Full Text] [Related]
16. Indications for Contralateral Prophylactic Mastectomy: A Consensus Statement Using Modified Delphi Methodology.
Wright FC; Look Hong NJ; Quan ML; Beyfuss K; Temple S; Covelli A; Baxter N; Gagliardi AR
Ann Surg; 2018 Feb; 267(2):271-279. PubMed ID: 28594745
[TBL] [Abstract][Full Text] [Related]
17. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
19. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
20. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
